iBio IBIO Stock News

iBio Inc (NYSEAMERICAN: IBIO) is making a run for the top in the market this morning, trading on gains around 20% in the premarket. The gains come after the company announced that it is moving forward with a second COVID-19 vaccine program. Here’s the scoop:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

IBIO Stock Is Climbing On New COVID-19 Vaccine Program

In a press release issued this morning, iBio announced that it has initiated preclinical immunization studies for a second COVID-19 vaccine platform. The company said that the new vaccine program is named IBIO-201.

The program combines antigens derived from the SARS-CoV-2 spike protein fused with the company’s patented lichenase booster molecule, also known as LicKM. LicKM was designed by IBIO to enhance immune response.

In the release, the company said that the addition of the LicKM booster to a subunit antigen is expected to improve the likelihood of achieving single-dose, prolonged immunity. Moreover, the inclusion of LicKM is expected to increase manufacturing capacity through increased potency.

In the release, the company said that the new vaccine will be tested at Texas A&M University System laboratories as part of the Master Joint Development Agreement established between the two in 2016.

In a statement, Tom Isett, Co-Chairman and CEO at IBIO, had the following to offer:

The launch of our second COVID-19 vaccine program is emblematic of the speed, flexibility and scalability we can achieve by combining our plant-based FastPharming Systemâ„¢ with other technologies in our intellectual property portfolio, such as LicKM. As a company with purpose-built pandemic response capabilities, we are pleased that in a matter of weeks we successfully discovered and advanced two promising, unique, internally-developed, COVID-19 vaccine programs into IND-enabling studies. Equally important is that our plant-based system avoids resource-intensive scale-up challenges associated with traditional manufacturing approaches so that we should be able to more rapidly produce high-quality material for hundreds of millions of doses upon regulatory clearance.

The above statement was followed up by Dr. Sylvain Marcel, VP of Protein Expression Sciences at IBIO. Here’s what he had to say:

One of the common challenges with soluble antigens is that they often require the use of an adjuvant to boost their immunogenicity. Our LicKM technology has the potential to achieve the same immune response as a soluble antigen vaccine approach, but with lower vaccine antigen requirements. This may prove to be valuable in reducing the number of vaccine doses necessary to establish prolonged immunity.

Don’t Forget The FastPharming Facility

iBio is a very important player when it comes to the race to develop a vaccine for COVID-19. Not only does the company now have two vaccine development programs underway, it also has the FastPharming Facility, an important tool in the fight against the pandemic.

The FastPharming Facility was developed specifically for the purpose of manufacturing vaccines, treatments, and other biological agents during pandemics. The goal was to create a facility that had the ability to mass produce vaccines and other biological agents faster than any other facility would allow.

So, not only does IBIO have two vaccine development programs underway, if these programs make their way to regulatory approval, it’s got manufacturing in the bag.

The Bottom Line

The bottom line here is that iBio is a key competitor in the race to develop and manufacture a COVID-19 vaccine. With the news today, the company now has two development programs dedicated to protecting consumers from the virus. This, combined with the company’s FastPharming Facility creates a significant advantage over its competitors.

For these reasons, IBIO is a stock that’s well worth watching.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required


LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.